Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model

Carleen Cullinane, Charmaine M. Jeffery, Peter D. Roselt, Ellen M. van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J. Harris, Rodney J. Hicks and Paul S. Donnelly
Journal of Nuclear Medicine December 2020, 61 (12) 1800-1805; DOI: https://doi.org/10.2967/jnumed.120.243543
Carleen Cullinane
1Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
2Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charmaine M. Jeffery
3Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Roselt
4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen M. van Dam
3Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Jackson
2Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Kuan
5Molecular Imaging and Therapy Research Unit, SAHMRI, Adelaide, South Australia, Australia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Price Jackson
4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Binns
4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica van Zuylekom
2Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Harris
3Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney J. Hicks
1Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul S. Donnelly
6School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 12 1800-1805
DOI 
https://doi.org/10.2967/jnumed.120.243543
PubMed 
32414949

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 13, 2020
  • Accepted for publication April 16, 2020
  • Published online December 1, 2020.

Article Versions

  • previous version (May 15, 2020 - 05:25).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Carleen Cullinane1,2,
  2. Charmaine M. Jeffery3,
  3. Peter D. Roselt4,
  4. Ellen M. van Dam3,
  5. Susan Jackson2,
  6. Kevin Kuan5,
  7. Price Jackson4,
  8. David Binns4,
  9. Jessica van Zuylekom2,
  10. Matthew J. Harris3,
  11. Rodney J. Hicks1,4 and
  12. Paul S. Donnelly6
  1. 1Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
  2. 2Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  3. 3Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia
  4. 4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  5. 5Molecular Imaging and Therapy Research Unit, SAHMRI, Adelaide, South Australia, Australia; and
  6. 6School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia
  1. For correspondence or reprints contact either of the following: Paul S. Donnelly, School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, 3010, Victoria, Australia. E-mail: pauld{at}unimelb.edu.auRodney J. Hicks, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, 3010, Victoria, Australia. E-mail: rod.hicks{at}petermac.org
View Full Text

Statistics from Altmetric.com

Cited By...

  • 44 Citations
  • 52 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
    Katherine A. Morgan, Stacey E. Rudd, Asif Noor, Paul S. Donnelly
    Chemical Reviews 2023 123 20
  • New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
    Emilia Fortunati, Giulia Argalia, Lucia Zanoni, Stefano Fanti, Valentina Ambrosini
    Current Treatment Options in Oncology 2022 23 5
  • Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT
    Guiyang Hao, Tara Mastren, William Silvers, Gedaa Hassan, Orhan K. Öz, Xiankai Sun
    Scientific Reports 2021 11 1
  • 67Cu Production Capabilities: A Mini Review
    Liliana Mou, Petra Martini, Gaia Pupillo, Izabela Cieszykowska, Cathy S. Cutler, Renata Mikołajczak
    Molecules 2022 27 5
  • Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues
    Qing Bo, Fan Yang, Yingge Li, Xianyu Meng, Huanhuan Zhang, Yingxin Zhou, Shenglong Ling, Demeng Sun, Pei Lv, Lei Liu, Pan Shi, Changlin Tian
    Cell Discovery 2022 8 1
  • Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals
    Olga O. Krasnovskaya, Daniil Abramchuck, Alexander Erofeev, Peter Gorelkin, Alexander Kuznetsov, Andrey Shemukhin, Elena K. Beloglazkina
    International Journal of Molecular Sciences 2023 24 11
  • Copper and Copper Complexes in Tumor Therapy
    Yingqiao Wang, Tingxi Tang, Yi Yuan, Nan Li, Xiaoqing Wang, Jian Guan
    ChemMedChem 2024 19 11
  • Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
    Lachlan E. McInnes, Carleen Cullinane, Peter D. Roselt, Susan Jackson, Benjamin J. Blyth, Ellen M. van Dam, Nicholas A. Zia, Matthew J. Harris, Rodney J. Hicks, Paul S. Donnelly
    Journal of Nuclear Medicine 2021 62 6
  • Production Review of Accelerator-Based Medical Isotopes
    Yiwei Wang, Daiyuan Chen, Ricardo dos Santos Augusto, Jixin Liang, Zhi Qin, Juntao Liu, Zhiyi Liu
    Molecules 2022 27 16
  • Carrier systems of radiopharmaceuticals and the application in cancer therapy
    Taotao Zhang, Huiwen Lei, Xiaohua Chen, Zhihui Dou, Boyi Yu, Wei Su, Wei Wang, Xiaodong Jin, Takanori Katsube, Bing Wang, Hong Zhang, Qiang Li, Cuixia Di
    Cell Death Discovery 2024 10 1

Article usage

Article usage: May 2020 to April 2025

AbstractFullPdf
May 2020509056
Jun 2020191017
Jul 2020113014
Aug 2020130025
Sep 2020111013
Oct 2020107010
Nov 202078026
Dec 2020173491191
Jan 20214247464
Feb 20212591831
Mar 20212581534
Apr 20211691524
May 20212051331
Jun 20216010637
Jul 20212910545
Aug 2021368245
Sep 2021379364
Oct 2021299466
Nov 2021345354
Dec 2021276238
Jan 2022247348
Feb 2022235834
Mar 2022236542
Apr 2022296845
May 2022206857
Jun 2022223727
Jul 2022224929
Aug 2022215430
Sep 2022154020
Oct 2022183820
Nov 2022163322
Dec 2022164217
Jan 2023204231
Feb 202374621
Mar 2023164823
Apr 2023153537
May 2023288037
Jun 20231916527
Jul 20231516828
Aug 20232734125
Sep 20233524327
Oct 20232614530
Nov 20231931119
Dec 20232035726
Jan 20242416626
Feb 20241119722
Mar 20241311642
Apr 2024219543
May 2024229436
Jun 2024156217
Jul 2024168834
Aug 2024317734
Sep 2024197521
Oct 20242910334
Nov 2024218630
Dec 2024248832
Jan 2025118129
Feb 20252113228
Mar 2025179336
Apr 20251913155
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (12)
Journal of Nuclear Medicine
Vol. 61, Issue 12
December 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Carleen Cullinane, Charmaine M. Jeffery, Peter D. Roselt, Ellen M. van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J. Harris, Rodney J. Hicks, Paul S. Donnelly
Journal of Nuclear Medicine Dec 2020, 61 (12) 1800-1805; DOI: 10.2967/jnumed.120.243543

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Carleen Cullinane, Charmaine M. Jeffery, Peter D. Roselt, Ellen M. van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J. Harris, Rodney J. Hicks, Paul S. Donnelly
Journal of Nuclear Medicine Dec 2020, 61 (12) 1800-1805; DOI: 10.2967/jnumed.120.243543
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors
  • Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • radiopharmaceuticals
  • 64Cu
  • 67Cu
  • peptide receptor radionuclide therapy
  • theranostics
SNMMI

© 2025 SNMMI

Powered by HighWire